Researchers have identified a specific set of biological markers in the blood that can predict the onset of dangerous arterial plaques in people living with HIV years before it becomes visible on a scan. The study, “Inflammation-associated Lipidomic Signatures Prior to Carotid Artery Atherosclerosis in People Living With HIV,” published in The Journal of Clinical Endocrinology & Metabolism, maps out a complex network of lipid metabolism and inflammation that appears to drive “silent” heart disease in this high-risk population.
Using advanced untargeted lipidomic profiling, scientists from Fudan University and the Shanghai Institute of Infectious Diseases analyzed hundreds of plasma lipid species. They discovered that specific “lipidomic signatures” — particularly those involving glycerophospholipid metabolism and short-chain fatty acids — are significantly altered in HIV-positive individuals who eventually develop subclinical carotid atherosclerosis (SCA), a precursor to strokes and heart attacks.
The findings are particularly critical for the modern management of HIV. While antiretroviral therapy has turned HIV into a manageable chronic condition, patients still face a disproportionately high risk of cardiovascular disease compared to the general population. This study suggests that even when the virus is suppressed, an underlying “collision” between metabolic imbalances and chronic inflammation continues to damage the vascular system. “Our findings underscore specific lipidomic-inflammatory networks that may underlie the heightened risk of atherosclerosis in HIV infection,” the study authors write.
As the HIV-positive population ages, the focus of care is rapidly shifting from viral suppression to the prevention of “age-related” complications. By uncovering the metabolic triggers of atherosclerosis, this research moves the medical community one step closer to a future where heart health is managed through personalized chemistry.
Using untargeted lipidomic profiling, scientists analyzed 649 plasma lipid species and 20 inflammatory markers. They found that a specific protein, interleukin (IL)-18, acted as a central hub. The researchers noted that “the differential involvement of IL-18 suggests a central role of NLRP3 inflammasome activation in HIV-associated vascular inflammation.”The study suggests that IL-18 may be a key indicator of NLRP3 inflammasome activation — a specific type of biological alarm system that triggers vascular inflammation.
The research followed a cohort of nearly 350 individuals, comparing HIV-positive patients who developed arterial plaque against both HIV-positive and HIV-negative controls. The data revealed that the metabolic shifts — specifically involving lysophospholipids — were present at baseline, long before the physical onset of atherosclerosis was detected.
This shift toward “precision medicine” mirrors broader trends in the industry. Much like the work being done by spatial biology leaders to map protein expression in tissues, this study provides a molecular map of how lipids and proteins interact in the bloodstream to degrade heart health.
Experts say the identification of these signatures offers a dual benefit: It provides a new way to screen high-risk patients early and points toward potential new drug targets that could block the inflammatory pathways leading to heart disease. As the HIV-positive population ages, the focus of care is rapidly shifting from viral suppression to the prevention of “age-related” complications. By uncovering the metabolic triggers of atherosclerosis, this research moves the medical community one step closer to a future where heart health is managed through personalized chemistry. Much like how spatial biology leaders map protein expression in tissues, this study provides a molecular map of how lipids and proteins interact in the bloodstream. By uncovering these metabolic triggers, doctors may soon be able to screen and treat high-risk patients long before a heart attack or stroke occurs.
Loading ...